PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today annou

US stock futures mixed, Dow futures up 0.2%. Frequency Electronics (FEIM) shares down 8.3% after rep

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers

US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,

CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes

CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reim

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds

The Federal Circuit's decision on Friday upheld the district court's findings that Nexus&#39

PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today annou

CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF

CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and reg

CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger executio

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announ

CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guida

CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitab

CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript

CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by conti

CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Est

Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.00

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consens

‒ Q1 2026 Net Revenue of  $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA o

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnin

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announ

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises

Citizens analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and m

Leerink Partners analyst Roanna Ruiz maintains Cormedix (NASDAQ:CRMD) with a Outperform and raise

CorMedix Inc. (NASDAQ:CRMD) shares are up on Monday following the announcement of positive topline r

CorMedix says Phase 3 ReSPECT data show rezafungin is non-inferior in fungal prevention, supporting

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price t

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in

CorMedix is entering a post-TDAPA reset, with DefenCath revenue expected to decline materially and n

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biophar

Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.0

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.61 per share which missed the analyst conse

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:CRMD) with a Buy and maintains

Here's a look at this week's earnings reports that are most likely to be watched by retail i

Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major